Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.024 | 0.7 |
mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |